Histotripsy of Pancreatic Cancer Liver Metastases: Early Outcomes and Imaging Findings

Tarub S Mabud; Monica Vergara; Jasper Du; Shu Liu; Frederic Bertino; Bedros Taslakian; Christopher Wolfgang; Mikhail Silk; D Brock Hewitt

doi:10.1002/wjs.12646

Histotripsy of Pancreatic Cancer Liver Metastases: Early Outcomes and Imaging Findings

World J Surg. 2025 Jul;49(7):1899-1902. doi: 10.1002/wjs.12646. Epub 2025 May 30.

Authors

Tarub S Mabud¹, Monica Vergara¹, Jasper Du¹, Shu Liu¹, Frederic Bertino¹, Bedros Taslakian¹, Christopher Wolfgang², Mikhail Silk¹, D Brock Hewitt²

Affiliations

¹ Department of Vascular and Interventional Radiology, NYU Langone Health, New York, New York, USA.
² Department of Hepatobiliary & Pancreatic Surgery, NYU Langone Health, New York, New York, USA.

PMID: 40445073
DOI: 10.1002/wjs.12646

Abstract

Patients with pancreatic ductal adenocarcinoma (PDAC) frequently present with liver metastases, which severely limit treatment options and prognosis. In other cancers, treatment of liver disease can improve outcomes and similar approaches are being explored in PDAC. Clinical data for locoregional control of pancreatic cancer liver metastases (PCLM) are limited, and histotripsy offers a new noninvasive tool for disease control. This study evaluates the preliminary safety, efficacy, and imaging findings of histotripsy in patients with PCLM.

MeSH terms

Aged
Carcinoma, Pancreatic Ductal* / diagnostic imaging
Carcinoma, Pancreatic Ductal* / secondary
Carcinoma, Pancreatic Ductal* / therapy
Female
High-Intensity Focused Ultrasound Ablation* / methods
Humans
Liver Neoplasms* / diagnostic imaging
Liver Neoplasms* / secondary
Liver Neoplasms* / surgery
Liver Neoplasms* / therapy
Male
Middle Aged
Pancreatic Neoplasms* / pathology
Retrospective Studies
Treatment Outcome